Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms
There are now a wide variety of therapeutic options for managing patients with cutaneous T-cell lymphoma-related symptoms. These include skin-directed therapies such as psoralen with UVA irradiation (PUVA), topical chemotherapies such as mechlorethamine (nitrogen mustard) and carmustine (BCNU), electron beam radiation, and systemic therapies such as chemotherapy, photopheresis, and interferons. Although treatment algorithms exist for patients with early stage disease, often treatments are individualized, based on patient specific factors, cost, and accessibility of referral centers for specialized therapies. This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient.
To access this article, please choose from the options below
This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.
Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals. Prof Bagot has served as a consultant to Zeneus. Prof Dummer has participated in scientific symposia and advisory boards sponsored by Zeneus and Ligand Pharmaceuticals.
PII: S0093-7754(05)00514-2
doi:10.1053/j.seminoncol.2005.12.020
© 2006 Elsevier Inc. All rights reserved.
